ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.654,15
0,86%
S&P 500
6.066,44
0,00%
US Dollar vs BRL
5,7735
-0,26%
Bitcoin
96.849,97
-0,65%
Brent Oil
76,815
1,17%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Dyne Therapeutics Inc (DYN)

  7. Dyne Therapeutics Inc (DYN) Notícias

DYN

Dyne Therapeutics (DYN)

Dyne Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DYN
DataHoraFonteTítuloCódigoCompanhia
03/02/202509:30GlobeNewswire Inc.Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:DYNDyne Therapeutics Inc
21/01/202509:30GlobeNewswire Inc.Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:DYNDyne Therapeutics Inc
10/01/202508:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
10/01/202508:30GlobeNewswire Inc.Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101NASDAQ:DYNDyne Therapeutics Inc
09/01/202509:30GlobeNewswire Inc.Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
08/01/202518:05GlobeNewswire Inc.Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
11/12/202422:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
11/12/202418:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
14/11/202411:27Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:DYNDyne Therapeutics Inc
12/11/202409:30GlobeNewswire Inc.Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:DYNDyne Therapeutics Inc
07/11/202418:15GlobeNewswire Inc.Dyne Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
09/10/202408:30GlobeNewswire Inc.Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular DiseasesNASDAQ:DYNDyne Therapeutics Inc
23/09/202409:56GlobeNewswire Inc.Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines ConferenceNASDAQ:DYNDyne Therapeutics Inc
03/09/202419:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
03/09/202407:31GlobeNewswire Inc.Dyne Therapeutics Announces Key Leadership AppointmentsNASDAQ:DYNDyne Therapeutics Inc
03/09/202407:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple CohortsNASDAQ:DYNDyne Therapeutics Inc
29/08/202408:30GlobeNewswire Inc.Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
14/08/202417:05Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:DYNDyne Therapeutics Inc
12/08/202418:10GlobeNewswire Inc.Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
12/08/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DYNDyne Therapeutics Inc
24/06/202408:30GlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseNASDAQ:DYNDyne Therapeutics Inc
13/06/202417:40GlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressNASDAQ:DYNDyne Therapeutics Inc
30/05/202408:30GlobeNewswire Inc.Dyne Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
28/05/202408:30GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
22/05/202417:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
21/05/202421:39GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202417:01GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202407:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
19/05/202409:00GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
02/05/202417:10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DYN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BOBR4
BOMBRIL PN
BOV
RCSL4
RECRUSUL PN
BOV
PRIO3
PETRORIO ON
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
TELB4
TELEBRAS PN
BOV
USIM5
USIMINAS PNA
BOV
BMKS3
BIC MONARK ON
BOV
FICT3
Fictor Alimentos ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
COGN3
COGNA ON
BOV
BMIN4
MERC INVEST PN
BOV
IFCM3
Infracommerce Caxaas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios